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Aim
We aimed to assess the benefits and safety of low dose
growth hormone treatment (GHT, 4.5 mg/m2/week) in
young children with genetically confirmed Prader-Willi
Syndrome (PWS).
Methods
Data of 20 infants (2-12 months) and 24 toddlers (13-24
months) were collected from the PWS-OZGROW data-
base. The two groups were evaluated for standard devia-
tion scores (SDS) of height (length under age 2 years),
weight and BMI using the World Health Organization
standards (SDSWHO) and PWS specific BMI (SDSPWS),
bone age (BA), insulin-like growth factor-1 (IGF-1)
levels, hypotonia, developmental delay, spinal curvature,
sleep studies and adverse events over 2 years of GHT.
Results
At commencement of GHT infants had a reduced BMI
SDSWHO (P=0.003), while toddlers had a reduced height
SDSWHO (P=0.014). The height/length SDSWHO of infants
increased from -1.09±1.15 at baseline to -0.26±0.89 after
one year and -0.02±0.80 after two years GHT (GLM
repeated measures; P < 0.0001,) and in toddlers increased
from -2.11±1.45 to -1.11±1.11 and -0.87±0.94 (P <
0.0001). BMI SDSWHO increased in both groups (data not
shown), while BMI SDSPWS decreased (P < 0.0001, age
groups P > 0.05) from 0.40±0.84 to -0.07±0.67 at Year 1
and -0.31±0.95 at Year 2 (both age groups combined). Pre-
term and full term children did not differ significantly in
response to GHT, nor did children with deletion (14) and
uniparental disomy (16). All children had low to very low
serum IGF-1 at baseline which increased to within the
normal reference range for the majority of children (61%)
with the remainder modestly increased during the first
2 years of treatment. An improvement in tone, spinal cur-
vature and developmental delay was noted in those who
were more severely affected at baseline. Two children
developed scoliosis. Three children ceased GHT tempora-
rily to adjust positive airway pressure settings or for tonsil-
lectomy following onset or worsening of obstructive and/
or central sleep apnoea. Bone age was not advanced and
no other serious adverse events were reported during the
two year GHT.
Conclusion
Treating young children (<2 yrs) with PWS with 4.5 mg/m2/
week of GH normalises height and achieves IGF-1 levels in
the normal range in the majority of patients. The risk of
respiratory adverse events can be minimised by regular
monitoring. The dose was sufficient to keep height and
most IGF-1 values in the normal range and PWS specific
BMI SDS in a negative range and may lower potential risks
of long-term treatment of very young children with PWS.
On behalf of the PWS and OZGROW collaboration
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